Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis. METHODS: We conducted two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) to evaluate the efficacy and safety of 150 mg of nintedanib twice daily as compared with placebo in patients with idiopathic pulmonary fibrosis. The primary end point was the annual rate of decline in forced vital capacity (FVC). Key secondary end points were the time to the first acute exacerbation and the change from baseline in the total score on the St. George's Respiratory Questionnaire, both assessed over a 52-week period. RESULTS: A total of 1066 patients were randomly assigned in a 3:2 ratio to receive nintedanib or placebo. The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1 and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2. In INPULSIS-1, there was no significant difference between the nintedanib and placebo groups in the time to the first acute exacerbation (hazard ratio with nintedanib, 1.15; 95% CI, 0.54 to 2.42; P=0.67); in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P=0.005). The most frequent adverse event in the nintedanib groups was diarrhea, with rates of 61.5% and 18.6% in the nintedanib and placebo groups, respectively, in INPULSIS-1 and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2. CONCLUSIONS: In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintedanib was frequently associated with diarrhea, which led to discontinuation of the study medication in less than 5% of patients. (Funded by Boehringer Ingelheim; INPULSIS-1 and INPULSIS-2 ClinicalTrials.gov numbers, NCT01335464 and NCT01335477.).
Overview
CoChat Summary
TL;DR
This paper reports two replicate 52-week phase 3 randomized trials showing that nintedanib slowed the decline in forced vital capacity in idiopathic pulmonary fibrosis. Diarrhea was common, but discontinuation due to study medication occurred in less than 5% of patients.
Key findings
- In INPULSIS-1, the adjusted annual rate of change in FVC was -114.7 ml with nintedanib vs -239.9 ml with placebo; the between-group difference was 125.3 ml (95% CI, 77.7 to 172.8; P<0.001).
- In INPULSIS-2, the adjusted annual rate of change in FVC was -113.6 ml with nintedanib vs -207.3 ml with placebo; the between-group difference was 93.7 ml (95% CI, 44.8 to 142.7; P<0.001).
- For time to first acute exacerbation, INPULSIS-1 showed no significant difference (HR 1.15, 95% CI, 0.54 to 2.42; P = 0.67), while INPULSIS-2 showed benefit with nintedanib (HR 0.38, 95% CI, 0.19 to 0.77; P = 0.005).
- The most frequent adverse event was diarrhea: 61.5% vs 18.6% in INPULSIS-1 and 63.2% vs 18.3% in INPULSIS-2 for nintedanib vs placebo, respectively; the conclusion states this led to discontinuation in less than 5% of patients.
Methods
- Two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) compared nintedanib 150 mg twice daily with placebo in patients with idiopathic pulmonary fibrosis.
- 1066 patients were randomly assigned in a 3:2 ratio to nintedanib or placebo.
- Primary outcome was the annual rate of decline in forced vital capacity (FVC); key secondary outcomes were time to first acute exacerbation and change in St. George’s Respiratory Questionnaire total score over 52 weeks.
Limitations
- The text does not state formal study limitations.
- Evident from the paper’s own reporting: the effect on acute exacerbation was inconsistent across the two replicate trials (no significant difference in INPULSIS-1, significant benefit in INPULSIS-2).
- Evident from the text: the provided excerpt does not report the full results for the St. George’s Respiratory Questionnaire outcome, so that secondary endpoint cannot be fully summarized from this text alone.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 1 Not valid · 0 Not checked · 11 Own results and interpretations
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“which led to discontinuation of the study medication in less than 5% of patients.”
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P = 0.005).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
5 more claims
Create a free account to see all 12 claims and every source verdict.
- It may state two separate claims as one. 1
- Probably not a substantial claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [192]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“nintedanib, which was originally developed with oncology in mind, for treatment of idiopathic pulmonary fibrosis150.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [150]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials investigating these two drugs in patients with IPF have demonstrated only a slowing of disease progression33,34, as measured by forced vital capacity (FVC) and self-reported quality of life (QOL) metrics, and unclear benefit to survival26, making the development of therapies that can restore lung function and reverse the course of disease a priority.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [34]
Experimental — accuracy not yet measured
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationThe St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Self-citationEfficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
Self-citationAcute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Self-citationBIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
St. George's Respiratory Questionnaire: MCID
Jones, P. W. (2005) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200050513 · Cited by 855
Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome
Song, J. W., Hong, S.-B., Lim, C.-M., Koh, Y., & Kim, D. S. (2011) · European Respiratory Journal · doi:10.1183/09031936.00159709 · Cited by 783
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citation
Cited by
Items 1,301–1,400 of 4,628
Limited efficacy of nintedanib for idiopathic pleuroparenchymal fibroelastosis
Kinoshita, Y., Miyamura, T., Ikeda, T., Ueda, Y., Yoshida, Y., Kushima, H., & Ishii, H. (2022) · Respiratory Investigation · doi:10.1016/j.resinv.2022.03.001 · Cited by 36
Raghu, G., Hamblin, M. J., Brown, A., Golden, J. A., Ho, L. A., Wijsenbeek, M. S., Vašáková, M., Pesci, A., Antin-Ozerkis, D. E., Meyer, K. C., et al. (2022) · Respiratory Research · doi:10.1186/s12931-022-02047-0 · Cited by 33
Self-citationFujita, K., Ohkubo, H., Nakano, A., Mori, Y., Fukumitsu, K., Fukuda, S., Kanemitsu, Y., Uemura, T., Tajiri, T., Maeno, K., et al. (2022) · Chronic Respiratory Disease · doi:10.1177/14799731221117298 · Cited by 37
Hoffmann‐Vold, A., Volkmann, E. R., Allanore, Y., Assassi, S., Vries-Bouwstra, J. K. D., Smith, V. M., Tschoepe, I., Loaiza, L., Kanakapura, M., & Distler, O. (2022) · The Lancet Rheumatology · doi:10.1016/s2665-9913(22)00215-6 · Cited by 34
Onishchenko, D., Marlowe, R. J., Ngufor, C. G., Faust, L. J., LIMPER, A. H., Hunninghake, G. M., Martínez, F. J., & Chattopadhyay, I. (2022) · Nature Medicine · doi:10.1038/s41591-022-02010-y · Cited by 40
Zhang, Q., Ye, W., Liu, Y., Decao, N., Zhao, X., Li, G., Qu, Y., & Zhao, Z. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114018 · Cited by 34
“The research shows that oxidation imbalance, inflammatory injury, and excessive accumulation of ECM result in PF [7,8].”
BackgroundA novel segmental challenge model for bleomycin-induced pulmonary fibrosis in sheep
Organ, L. A., Bacci, B., Koumoundouros, E., Barcham, G., Kimpton, W. G., Nowell, C. J., Samuel, C. S., & Snibson, K. J. (2014) · Experimental Lung Research · doi:10.3109/01902148.2014.985806 · Cited by 30
Inhibitory effects of amines from Citrus reticulata on bleomycin-induced pulmonary fibrosis in rats
Zhou, X., CAO, Z.-D., Xiao, N., Shen, Q., & Li, J. (2015) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2015.2435 · Cited by 30
Iwasawa, T., Takemura, T., Okudera, K., Gotoh, T., Iwao, Y., Kitamura, H., Baba, T., Ogura, T., & Oba, M. S. (2017) · European Journal of Radiology · doi:10.1016/j.ejrad.2017.02.037 · Cited by 32
Acute exacerbations of interstitial lung disease: lessons from idiopathic pulmonary fibrosis
Spagnolo, P., & Wuyts, W. A. (2017) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000405 · Cited by 36
Pirfenidone and Nintedanib for Treatment of Idiopathic Pulmonary Fibrosis
Sathiyamoorthy, G., Sehgal, S., & Ashton, R. W. (2017) · Southern Medical Journal · doi:10.14423/smj.0000000000000655 · Cited by 30
Wu, Q., Zhou, Y., Feng, F., & Zhou, X. (2018) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-017-2429-5 · Cited by 29
Zhu, M., An, Y., Zhang, X., Wang, Z., & Duan, H. (2019) · Cell and Tissue Research · doi:10.1007/s00441-019-03054-2 · Cited by 30
Fibrotic Response to Biomaterials and all Associated Sequence of Fibrosis
Jones, K. S. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800196-7.00009-8 · Cited by 43
Federal clinical guidelines on diagnosis and treatment of idiopathic pulmonary fibrosis
Avdeev, S. N., Айсанов, З. Р., Belevskiy, А. S., Ilkovich, M. M., Коган, Е. А., Мержоева, З. М., Petrov, D., Samsonova, M. V., Terpigorev, S. A., Трушенко, Н. В., et al. (2022) · PULMONOLOGIYA · doi:10.18093/0869-0189-2022-32-3-473-495 · Cited by 32
Qin, S., Tan, P., Xie, J., Zhou, Y., & Zhao, J. (2023) · Chinese Medicine · doi:10.1186/s13020-023-00797-7 · Cited by 34
Commensal Oral Microbiota, Disease Severity, and Mortality in Fibrotic Lung Disease
O’Dwyer, D. N., Kim, J. S., Ma, S., Ranjan, P., Das, P., Lipinski, J. H., Metcalf, J. D., Falkowski, N. R., Yow, E. S., Anstrom, K. J., et al. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202308-1357oc · Cited by 38
Jin, C., Chen, Y., Wang, Y., Li, J., Liang, J., Zheng, S., Zhang, L., Li, Q., Wang, Y., Ling, F., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-66947-5 · Cited by 43
Lung Cancer and Interstitial Lung Diseases
Drakopanagiotakis, F., Krauss, E., Michailidou, Ι., Drosos, V., Anevlavis, S., Guenther, A., & Steiropoulos, P. (2024) · Cancers · doi:10.3390/cancers16162837 · Cited by 39
“Nintedanib has also been approved for the treatment of IPF, as it was shown that it slows down the progression of the disease and reduces the risk of acute exacerbation at a dose of 150 mg bid [144].”
BackgroundCampitiello, R., Soldano, S., Gotelli, E., Hysa, E., Montagna, P., Casabella, A., Paolino, S., Pizzorni, C., Sulli, A., Smith, V. M., et al. (2024) · Autoimmunity Reviews · doi:10.1016/j.autrev.2024.103637 · Cited by 36
Vaccinia vaccine–based immunotherapy arrests and reverses established pulmonary fibrosis
Collins, S. L., Chan‐Li, Y., Oh, M. H., Vigeland, C. L., Limjunyawong, N., Mitzner, W., Powell, J. D., & Horton, M. R. (2016) · JCI Insight · doi:10.1172/jci.insight.83116 · Cited by 28
Oh, G., Lee, S., Karna, A., Kim, H., Shen, A., Pandit, A., Lee, S., Yang, S., & So, H. (2016) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2016.79.4.257 · Cited by 30
The safety and tolerability of nintedanib in the treatment of idiopathic pulmonary fibrosis
Cottin, V. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1338268 · Cited by 31
Self-citationClubbing in patients with fibrotic interstitial lung diseases
van Manen, M. J. G., Vermeer, L. C., Moor, C. C., Vrijenhoeff, R., Grutters, J. C., Veltkamp, M., & Wijsenbeek, M. S. (2017) · Respiratory Medicine · doi:10.1016/j.rmed.2017.10.021 · Cited by 28
Pharmacokinetics of Nintedanib in Subjects With Hepatic Impairment
Marzin, K., Kretschmar, G., Luedtke, D., Kraemer, S., Kuelzer, R., Schlenker‐Herceg, R., Schmid, U., Schnell, D., & Dallinger, C. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1025 · Cited by 28
Self-citationAntifibrotic effects of a novel pirfenidone derivative in vitro and in vivo
Ma, Z., Zhao, C., Chen, Q., Yu, C.-H., Zhang, H., Zhang, Z., Huang, W., & Shen, Z. (2018) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2018.10.006 · Cited by 31
Idiopathic Pulmonary Fibrosis: New and Emerging Treatment Options
Hewitt, R. J., & Maher, T. M. (2019) · Drugs & Aging · doi:10.1007/s40266-019-00647-y · Cited by 34
Kim, J. S., Anderson, M. R., Podolanczuk, A. J., Kawut, S. M., Allison, M., Raghu, G., Stukovsky, K. H., Hoffman, E. A., Tracy, R. P., Barr, R. G., et al. (2019) · CHEST Journal · doi:10.1016/j.chest.2019.10.011 · Cited by 30
Self-citationZhang, T., Liu, M., Gao, Y., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111475 · Cited by 29
Liu, X., Shao, Y., Zhang, X., Ji, X., Xie, M., & Liu, H. (2021) · Acta Histochemica · doi:10.1016/j.acthis.2021.151746 · Cited by 30
Wiertz, I. A., Moll, S. A., Seeliger, B., Barlo, N. P., van der Vis, J. J., Korthagen, N. M., Rijkers, G. T., Ruven, H. J. T., Grutters, J. C., Prasse, A., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061940 · Cited by 32
Case Report: Pirfenidone in the Treatment of Post-COVID-19 Pulmonary Fibrosis
Zhou, X., Yang, D., Kong, X., Wei, C., LvQiu, S., Wang, L., Lin, Y., Yin, Z., Zhou, Z., & Luo, H. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.925703 · Cited by 36
“Another drug is nintedanib, which can significantly reduce the absolute value of the drop in forced vital capacity (FVC) among IPF patients (12).”
BackgroundCameli, P., Alonzi, V., d’Alessandro, M., Bergantini, L., Pordon, E., Guerrieri, M., Refini, R. M., Sestini, P., & Bargagli, E. (2022) · Biomedicines · doi:10.3390/biomedicines10081973 · Cited by 32
Yang, M., Wu, Y., Liu, X., Zhao, C., Li, T., Li, T.-Q., Zhang, X., Jiang, H., Mao, B., & Liu, W. Q. (2023) · Respiratory Medicine · doi:10.1016/j.rmed.2023.107329 · Cited by 32
Antifibrotic effects of sodium-glucose cotransporter-2 inhibitors: A comprehensive review
Shakour, N., Karami, S., Iranshahi, M., Butler, A. E., & Sahebkar, A. (2023) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102934 · Cited by 35
Pharmacologic therapies for idiopathic pulmonary fibrosis, past and future
Staitieh, B. S., Renzoni, E. A., & Veeraraghavan, S. (2015) · Annals of Medicine · doi:10.3109/07853890.2014.991751 · Cited by 32
“The primary endpoint was the annual rate of decline in FVC (43).”
BackgroundExercise training in idiopathic pulmonary fibrosis
Vainshelboim, B., Fox, B. D., de Oliveira, J. J. F., & Kramer, M. R. (2015) · Expert Review of Respiratory Medicine · doi:10.1586/17476348.2016.1121104 · Cited by 30
Tsao, A. S., Moon, J., Wistuba, I. I., Vogelzang, N. J., Kalemkerian, G. P., Redman, M. W., Gandara, D. R., & Kelly, K. L. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.05.021 · Cited by 31
Astilbin ameliorates pulmonary fibrosis via blockade of Hedgehog signaling pathway
Zhang, J., Liu, H., Song, C., Zhang, J., Wang, Y., Lv, C., & Song, X. (2018) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2018.03.006 · Cited by 31
Tissue-informed engineering strategies for modeling human pulmonary diseases
Bailey, K. E., Floren, M. L., D’Ovidio, T. J., Lammers, S. R., Stenmark, K. R., & Magin, C. M. (2018) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00353.2018 · Cited by 34
“Given the severity of IPF, surprisingly few therapeutic treatments are currently available to manage symptoms, and none have been shown to improve survival rates (83, 141).”
BackgroundMackintosh, J. A., Desai, S. R., Adamali, H. I., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.02412-2018 · Cited by 29
Vancheri, C., Sebastiani, A., Tomassetti, S., Pesci, A., Rogliani, P., Tavanti, L. M., Luppi, F., Harari, S. A., Rottoli, P., Ghirardini, A., et al. (2019) · Respiratory Medicine · doi:10.1016/j.rmed.2019.08.006 · Cited by 30
Wuyts, W. A., Dahlqvist, C., Slabbynck, H., Schlesser, M., Gusbin, N., Compère, C., Maddens, S., Lee, Y.-C., Kirchgaessler, K.-U., Bartley, K., et al. (2019) · Respiratory Research · doi:10.1186/s12931-019-1182-z · Cited by 31
De Biasi, S., Cerri, S., Bianchini, E., Gibellini, L., Persiani, E., Montanari, G., Luppi, F., Carbonelli, C. M., Zucchi, L., Bocchino, M., et al. (2015) · BMC Medicine · doi:10.1186/s12916-015-0515-0 · Cited by 28
Self-citationZamparelli, S. S., Sanduzzi, A., & Bocchino, M. (2023) · Diagnostics · doi:10.3390/diagnostics13142437 · Cited by 34
“Based on this, the paramount significance of achieving an accurate and early diagnosis, along with the timely initiation of disease-specific therapy, becomes evident to alter the outcome [3,4].”
BackgroundMethodMaher, T. M., Assassi, S., Azuma, A., Cottin, V., Hoffmann-Vold, A.-M., Kreuter, M., Oldham, J. M., Richeldi, L., Valenzuela, C., Wijsenbeek, M. S., et al. (2023) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2022-001580 · Cited by 28
Self-citationDual Barrier‐Penetrating Inhaled Nanoparticles for Enhanced Idiopathic Pulmonary Fibrosis Therapy
Yang, M., Han, M., Ling, T., Bi, Y., Li, X., Jeong, J., Wang, Y., & Jiang, H. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202315128 · Cited by 30
Mortality trends in idiopathic pulmonary fibrosis in Europe between 2013 and 2018
Gonnelli, F., Bonifazi, M., & Hubbard, R. (2024) · European Respiratory Journal · doi:10.1183/13993003.02080-2023 · Cited by 30
Lu, W., Teoh, A. K. Y., Waters, M., Haug, G., Shakeel, I., Hassan, M. I., Shahzad, A. M., Larsson‐Callerfelt, A., Piccari, L., & Sohal, S. S. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108757 · Cited by 37
An aging bone marrow exacerbates lung fibrosis by fueling profibrotic macrophage persistence
Farhat, A., Radhouani, M., Deckert, F., Zahalka, S., Pimenov, L., Fokina, A., Hakobyan, A., Oberndorfer, F., Brösamlen, J., Hladik, A., et al. (2025) · Science Immunology · doi:10.1126/sciimmunol.adk5041 · Cited by 38
Ohkouchi, S., Ono, M., Kobayashi, M., Hirano, T., Tojo, Y., Hisata, S., Ichinose, M., Irokawa, T., Ogawa, H., & Kurosawa, H. (2015) · Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine · doi:10.4137/ccrpm.s23285 · Cited by 28
Idiopathic pulmonary fibrosis: the turning point is now!
Funke, M., & Geiser, T. (2015) · Swiss Medical Weekly · doi:10.4414/smw.2015.14139 · Cited by 38
Plantier, L., Renaud, H., Respaud, R., Marchand-Adam, S., & Crestani, B. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17122091 · Cited by 30
Vessally, E., Hosseinzadeh‐Khanmiri, R., Ghorbani‐Kalhor, E., et al. (2017) · RSC Advances · doi:10.1039/c7ra01371j · Cited by 28
Idiopathic pulmonary fibrosis: a holistic approach to disease management in the antifibrotic age
Shaw, J., Marshall, T., Morris, H. G., Hayton, C., & Chaudhuri, N. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.10.111 · Cited by 34
Feifukang ameliorates pulmonary fibrosis by inhibiting JAK-STAT signaling pathway
Li, H., Wang, Z., Zhang, J., Wang, Y., Yu, C., Zhang, J., Song, X., & Lv, C. (2018) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-018-2297-3 · Cited by 27
Skandamis, A., Kani, C., Markantonis, S. L., & Souliotis, K. N. (2019) · Journal of Drug Assessment · doi:10.1080/21556660.2019.1597726 · Cited by 35
Hachisu, Y., Murata, K., Takei, K., Tsuchiya, T., Tsurumaki, H., Koga, Y., Horie, T., Takise, A., & Hisada, T. (2019) · Medicina · doi:10.3390/medicina55050132 · Cited by 29
“The antifibrotic agent, nintedanib has been reported to exert suppressive effects on AE-IPF [18] and is expected to regulate IPF pathology.”
BackgroundMorphological and molecular motifs of fibrosing pulmonary injury patterns
Jonigk, D. D., Stark, H., Braubach, P., Neubert, L., Shin, H., Izykowski, N., Welte, T., Janciauskiene, S. M., Warnecke, G., Haverich, A., et al. (2019) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.141 · Cited by 28
Saketkoo, L. A., Scholand, M. B., Lammi, M. R., & Russell, A. (2020) · Journal of Scleroderma and Related Disorders · doi:10.1177/2397198320904178 · Cited by 29
Lung transplantation for idiopathic pulmonary fibrosis
Pavec, J. L., Dauriat, G., Gazengel, P., Dolidon, S., Hanna, A., Feuillet, S., Pradère, P., Crutu, A., Florea, V., Boulate, D., et al. (2020) · La Presse Médicale · doi:10.1016/j.lpm.2020.104026 · Cited by 33
Jones, S. A., McGovern, M. M., Lidove, O., Giugliani, R., Mistry, P. K., Dionisi‐Vici, C., Muñoz‐Rojas, M. V., Nalysnyk, L., Schecter, A. D., & Wasserstein, M. (2020) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2020.06.008 · Cited by 30
Khanna, D., Tashkin, D. P., Wells, A. U., Seibold, J. R., Wax, S. D., Vazquez‐Mateo, C., Fleuranceau-Morel, P., Damian, D., & Denton, C. P. (2020) · The Journal of Rheumatology · doi:10.3899/jrheum.191365 · Cited by 28
Alqalyoobi, S., Pérez, E. R. F., & Oldham, J. M. (2020) · BMC Pulmonary Medicine · doi:10.1186/s12890-020-01328-y · Cited by 33
Chronic Lung Allograft Dysfunction: Review of CT and Pathologic Findings
Byrne, D., Nádor, R. G., English, J. C., Yee, J., Levy, R. D., Bergeron, C., Swiston, J. R., Mets, O. M., Müller, N. L., & Bilawich, A.-M. (2021) · Radiology Cardiothoracic Imaging · doi:10.1148/ryct.2021200314 · Cited by 32
Campo, A., González‐Ruiz, J. M., Andreu, E. J., Alcaide, A. B., Ocón, M. D. M., de-Torres, J. P., Pueyo, J. C., Cordovilla, R., Villarón, E. M., Sanchez-Guijo, F. M., et al. (2021) · ERJ Open Research · doi:10.1183/23120541.00773-2020 · Cited by 32
Kamiya, H., & Panlaqui, O. M. (2021) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01502-w · Cited by 30
Importance of chest HRCT in the diagnostic evaluation of fibrosing interstitial lung diseases
Torres, P. P. T. E. S., Rabahi, M. F., Moreira, M. A. C., Escuissato, D. L., Meirelles, G. D. S. P., & Marchiori, E. D. S. (2021) · Jornal Brasileiro de Pneumologia · doi:10.36416/1806-3756/e20200096 · Cited by 42
López-Matencio, J. M. S., Gómez, M., Vicente‐Rabaneda, E. F., González-Gay, M. Á., Ancochea, J., & Castañeda, S. (2021) · Pharmaceuticals · doi:10.3390/ph14080819 · Cited by 32
Khan, F. A., Stewart, I. D., Moss, S., Fabbri, L., Robinson, K. A., Johnson, S., & Jenkins, G. R. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202109-2091oc · Cited by 32
Liang, M., Matteson, E. L., Abril, A., & Distler, J. H. W. (2022) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x221074457 · Cited by 34
Plumbagin attenuates Bleomycin-induced lung fibrosis in mice
Mehdizadeh, S., Taherian, M., Bayati, P., Mousavizadeh, K., Pashangzadeh, S., Anisian, A., & Mojtabavi, N. (2022) · Allergy Asthma and Clinical Immunology · doi:10.1186/s13223-022-00734-7 · Cited by 28
Angiopoietin-like 4 Is a Critical Regulator of Fibroblasts during Pulmonary Fibrosis Development
Saito, S., Kitabatake, M., Ouji-Sageshima, N., Ogawa, T., Oda, A., Nishimura, T., Nishioka, T., Fushimi, S., Hara, A., Shichino, S., et al. (2023) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2022-0304oc · Cited by 31
Exploring computer-based imaging analysis in interstitial lung disease: opportunities and challenges
Felder, F. N., & Walsh, S. L. F. (2023) · ERJ Open Research · doi:10.1183/23120541.00145-2023 · Cited by 33
Targeting defective Toll-like receptor-3 function and idiopathic pulmonary fibrosis
O’Dwyer, D. N., Armstrong, M. E., Kooblall, M., & Donnelly, S. C. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.988706 · Cited by 29
Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage
Ryerson, C. J., Kolb, M. R. J., Richeldi, L., Lee, J. S., Wachtlin, D., Stowasser, S., & Poletti, V. E. (2019) · ERJ Open Research · doi:10.1183/23120541.00127-2018 · Cited by 30
Self-citationLu, G., Zhang, J., Liu, X., Liu, W., Cao, G., Lv, C., Zhang, X., Xu, P., Li, M., & Song, X. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14550 · Cited by 38
Enriched collagen solution as a pulp dressing in pulpotomized teeth in monkeys.
Fuks, A. B., Michaeli, Y., Sofer-Saks, B., & Shoshan, S. (1984) · PubMed · Cited by 31
Control of fibrosis with enhanced safety via asymmetric inhibition of prolyl‐tRNA synthetase 1
Yoon, I., Kim, S., Cho, M., You, K. A., Son, J., Lee, C., Suh, J. H., Bae, D., Kim, J. M., Oh, S., et al. (2023) · EMBO Molecular Medicine · doi:10.15252/emmm.202216940 · Cited by 22
PGF2α signaling drives fibrotic remodeling and fibroblast population dynamics in mice
Rodríguez, L. R., Tang, S. Y., Barboza, W. R., Murthy, A., Tomer, Y., Cai, T., Iyer, S., Chavez, K., Das, U. S., Ghosh, S., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.172977 · Cited by 29
Karampitsakos, Τ., Galaris, A., Chrysikos, S., Παπαϊωάννου, Ο., Vamvakaris, I. N., Barbayianni, I., Kanellopoulou, P., Grammenoudi, S., Anagnostopoulos, N., Stratakos, G. K., et al. (2023) · Respiratory Research · doi:10.1186/s12931-023-02551-x · Cited by 30
Tertiary lymphoid structures and B-cell infiltration are IPF features with functional consequences
Cocconcelli, E., Balestro, E., Turato, G., Fiorentù, G., Bazzan, E., Biondini, D., Tinè, M., Bernardinello, N., Pezzuto, F., Baraldo, S., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1437767 · Cited by 36
McCall, A. S., Gutor, S. S., Tanjore, H., Burman, A., Sherrill, T. P., Chapman, M., Calvi, C. L., Han, D., Camarata, J. E., Hunt, R. P., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adk8623 · Cited by 39
Targeting DNA damage in ageing: towards supercharging DNA repair
Bujarrabal-Dueso, A., Garinis, G. A., Robbins, P. D., Vijg, J., & Schumacher, B. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01212-6 · Cited by 38
Recent advances in connective tissue disease related interstitial lung disease
Suzuki, A., Kondoh, Y., & Fischer, A. (2017) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2017.1335600 · Cited by 30
Lassenius, M. I., Toppila, I., Pöntynen, N., Kasslin, L., Kaunisto, J., Kilpeläinen, M., & Laitinen, T. (2019) · European Clinical Respiratory Journal · doi:10.1080/20018525.2019.1702618 · Cited by 36
“Additionally, clinical studies with pirfenidone and nintedanib show that early initiation of disease modifying treatment can postpone irreversible deteriorative changes in lung function [2,12,13,15].”
BackgroundCarter, D. C., Wright, B., Jerome, W. G., Rose, J. P., & Wilson, E. J. (2020) · Journal of Nanomaterials · doi:10.1155/2020/4297937 · Cited by 27
“Currently, FDA-approved therapeutics for IPF only address factors which may improve symptoms or slow disease progression [20, 21] and many of the widely prescribed therapeutics for IPF have serious side effects which limit their effectiveness.”
BackgroundCaliskan, C., Seeliger, B., Jäger, B., Fuge, J., Welte, T., Terwolbeck, O., Freise, J., van Moorsel, C. H. M., Zhang, Y., & Prasse, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061993 · Cited by 28
Shochet, G. E., Pham, S., Beck, S., Naiel, S., Mekhael, O., Revill, S. D., Hayat, A. I., Vierhout, M., Bardenstein-Wald, B., Shitrit, D., et al. (2020) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2020.101933 · Cited by 28
Self-citationMoore, I., Wrobel, J. P., Rhodes, J. E., Lin, Q., Webster, S. E., Jo, H. E., Troy, L. K., Grainge, C., Glaspole, I., Corte, T. J., et al. (2020) · BMC Pulmonary Medicine · doi:10.1186/s12890-020-01297-2 · Cited by 27
Zhang, J., Chen, X., Chen, H., Li, R., Xu, P., Lv, C., Liu, B., & Song, X. (2020) · Pharmaceutical Biology · doi:10.1080/13880209.2020.1834590 · Cited by 28
“Hence, additional research needs to be done to explore new drugs to treat pulmonary fibrosis (King et al. 2014; Richeldi et al. 2014).”
BackgroundMachahua, C., Guler, S. A., Horn, M. P., Planas‐Cerezales, L., Montes‐Worboys, A., Geiser, T., Molina‐Molina, M., & Funke-Chambour, M. (2021) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2020-000827 · Cited by 29
Kindlin-2 Acts as a Key Mediator of Lung Fibroblast Activation and Pulmonary Fibrosis Progression
Zhang, P., Wang, J., Luo, W., Yuan, J., Cui, C., Guo, L., & Wu, C. (2021) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2020-0320oc · Cited by 29
Interstitial lung abnormality (ILA) and nonspecific interstitial pneumonia (NSIP)
Hino, T., Lee, K. S., Yoo, H., Han, J., Franks, T. J., & Hatabu, H. (2021) · European Journal of Radiology Open · doi:10.1016/j.ejro.2021.100336 · Cited by 28
Durheim, M. T., Bendstrup, E. M., Carlson, L., Sutinen, E., Hyldgaard, C., Kalafatis, D., Myllärniemi, M., Sköld, C. M., & Sjåheim, T. (2021) · Respirology · doi:10.1111/resp.14116 · Cited by 32
Ghosh, A., Hobbs, B. D., Yun, J. H., Saferali, A., Moll, M. R., Xu, Z., Chase, R., Morrow, J. D., Ziniti, J. P., Sciurba, F. C., et al. (2022) · Respiratory Research · doi:10.1186/s12931-022-02013-w · Cited by 30
Self-citationWang, D., Deng, B., Cheng, L., Li, J., Zhang, J., Zhang, X., Guo, X., Yan, T., Xin, Y., An, Y., et al. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.09.001 · Cited by 25
“Kunming mice were randomly divided into 10 groups (5 female and 5 male mice): (1) PBS control; (2) DR8 (0.”
MethodPlasticity towards Rigidity: A Macrophage Conundrum in Pulmonary Fibrosis
Sari, E., He, C., & Margaroli, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911443 · Cited by 29
Li, S., Zhang, G., Feng, G., Jiang, L., Chen, Z., Xin, W., & Zhang, X. (2022) · Pharmaceuticals · doi:10.3390/ph15101276 · Cited by 30
Chandra, S., Tan, E. Y., Empeslidis, T., & Sivaprasad, S. (2023) · Eye · doi:10.1038/s41433-023-02610-z · Cited by 28
Metadata
- Authors
- Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., Kim, D. S., Kolb, M., Nicholson, A. G., Noble, P. W., Selman, M., Taniguchi, H., Brun, M., Le Maulf, F., Girard, M., Stowasser, S., Schlenker-Herceg, R., Disse, B., & Collard, H. R.
- Affiliations
- NIHR Southampton Respiratory Biomedical Research Unit (GB)
- University of Washington (US)
- Nippon Medical School (JP)
- Ruhrlandklinik (DE)
- Université de Lyon (FR)
- Michigan Medicine (US)
- Royal Brompton & Harefield NHS Foundation Trust (GB)
- NHO Kinki Chuo Chest Medical Center (JP)
- Asan Medical Center (KR)
- McMaster University (CA)
- Cedars-Sinai Medical Center (US)
- Instituto Nacional de Enfermedades Respiratorias (MX)
- Tosei General Hospital (JP)
- Boehringer Ingelheim (Germany) (DE)
- University of California, San Francisco (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2071-2082
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2138871107
- Cited by
- 4,654
- References
- 21
- Citations by year
- 2026: 338 · 2025: 372 · 2024: 479 · 2023: 412 · 2022: 429 · 2021: 501 · 2020: 423 · 2019: 350 · 2018: 345 · 2017: 328 · 2016: 293 · 2015: 292 · 2014: 74
- FWCI
- 263.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Use Siena air (University of Siena) (submittedVersion, cc-by-nc-nd)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Digital Access to Libraries (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Amgen
- Pfizer
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Biogen
- Celgene
- FibroGen
- Ikaria
- University Hospital Southampton NHS Foundation Trust
- Massachusetts Medical Society
- Royal Brompton and Harefield NHS Foundation Trust
- Galecto
- Veracyte
- National Institute for Health and Care Research (NF-SI-0512-10157)
- Imperial College London
- Shionogi
- Genentech
- Japan Society for the Promotion of Science (24591149)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- nintedanib, idiopathic pulmonary fibrosis, tyrosine kinase inhibitors, forced vital capacity decline, acute exacerbation, St George's Respiratory Questionnaire, drug safety, INPULSIS trials, lung function preservation, adverse events, diarrhea, liver enzymes, proteinuria, thrombocytopenia, neutropenia, antifibrotic therapy
- MeSH terms
- Aged, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Indoles, Male, Middle Aged, Protein-Tyrosine Kinases, Quality of Life, Vital Capacity, Treatment Outcome, Disease Progression, Protein Kinase Inhibitors, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.